Acute effects of bisphosphonates on new and traditional markers of bone resorption.
Bisphosphonates are known to be potent inhibitors of osteoclast activity and their only clinically relevant effect in the short-term is the selective inhibition of bone resorption. The purpose of this study was to compare the response to the intravenous administration of two bisphosphonates, clodronate and alendronate, of several biochemical markers of bone resorption, including tartrate-resistant acid phosphatase (TRAP) and cross-linked carboxyterminal telopeptide of collagen I (ICTP) in serum and hydroxyproline (OHP), free pyridinium cross-links (Pyr), and cross-linked N-telopeptides of collagen I (NTx) in urine. The study was carried out on 11 osteoporotic and 12 Pagetic subjects of both sexes, treated with clodronate (600 mg/day for 2 days) or alendronate (5 mg/day for 2 days), and monitored for 28 days after bisphosphonate administration. All the urinary markers of bone resorption showed a prompt decline after bisphosphonates, with maximum reductions after 7-14 days: Pyr decreased by 43% +/- 9% and 42% +/- 22% (mean +/- SD), respectively in osteoporotic and pagetic subjects, OHP by 51% +/- 14% and 51% +/- 20%, and NTx by 55% +/- 15% and 65% +/- 26%. In the osteoporotic group, the urinary markers began to increase again at 30 days, though still remaining well below the basal level, whereas in the pagetic group, the excretion of all markers remained depressed until the end of the observation period. The reduction of NTx was significantly greater than that of Pyr and OHP in pagetic patients (P < 0.05) and tended to be greater than that of Pyr in osteoporotic patients (p = 0.07).(ABSTRACT TRUNCATED AT 250 WORDS)
Pedrazzoni
M
M
Istituto di Clinica Medica Generale e Terapia Medica, Università degli Studi di Parma, Italy.
Alfano
F S
FS
Gatti
C
C
Fantuzzi
M
M
Girasole
G
G
Campanini
C
C
Basini
G
G
Passeri
M
M
D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate; D000596:Amino Acids / Q000652:urine; D015415:Biomarkers / Q000097:blood / Q000652:urine; D001862:Bone Resorption / Q000188:drug therapy* / Q000378:metabolism; D001842:Bone and Bones / Q000503:physiopathology*; D004002:Clodronic Acid / Q000494:pharmacology*; D003094:Collagen / Q000097:blood / Q000652:urine; D024042:Collagen Type I; D004164:Diphosphonates / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy / Q000378:metabolism; D010024:Osteoporosis / Q000188:drug therapy / Q000378:metabolism; D010455:Peptides / Q000097:blood / Q000652:urine; D013997:Time Factors
D000596:Amino Acids; D015415:Biomarkers; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D004002:Clodronic Acid; C015484:pyridinoline; C036020:deoxypyridinoline; D003094:Collagen; D000135:Acid Phosphatase; D006909:Hydroxyproline; D019386:Alendronate